Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis - Takeaways - MDSpire

Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis

  • By

  • Adriana Krenz

  • Anna-Lena Krickl

  • Felix Burner

  • David Freudenstein

  • Constantin Träger

  • Timo Wirth

  • Luisa Klotz

  • Klemens Angstwurm

  • De-Hyung Lee

  • Ralf A. Linker

  • Stefanie Haase

  • June 15, 2026

  • 0 min

Share

  • 1

    Monoclonal antibodies targeting CD20-expressing B cells are effective therapies for multiple sclerosis.

  • 2

    Both intravenous and subcutaneous anti-CD20 therapies deplete CD19+ B cells and CD20+ T cells in patients.

  • 3

    Subcutaneous administration of ocrelizumab and ofatumumab results in higher percentages of memory B cells compared to intravenous ocrelizumab.

  • 4

    Patients switching from intravenous ocrelizumab to subcutaneous ofatumumab show an increase in memory B cells over time.

  • 5

    The study highlights the need for further analysis of the safety and efficacy profiles of different anti-CD20 therapies in multiple sclerosis.

Original Source(s)

Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis

  • by Adriana Krenz, Anna-Lena Krickl, Felix Burner, David Freudenstein, Constantin Träger, Timo Wirth, Luisa Klotz, Klemens Angstwurm, De-Hyung Lee, Ralf A. Linker, Stefanie Haase

  • June 15, 2026

Related Content

Editorial: Host-microbe immunometabolic chat: a new era of organismal communication

Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis